Oncolytics Biotech Inc是一家生物技术公司。该公司致力于开发pelareorep,一种静脉给药的免疫治疗剂,可激活先天性和适应性免疫系统并削弱肿瘤防御机制。它提高了免疫系统抗癌的能力,使肿瘤易受一系列肿瘤治疗的影响。该公司正在进行临床试验,评估pelareorep与检查点抑制剂和靶向治疗在实体和血液恶性肿瘤中的结合。Pelareorep的抗肿瘤活性基于三种模式:在允许的癌细胞中选择性病毒复制,导致肿瘤细胞裂解;针对感染激活先天免疫,导致趋化因子、细胞因子级联反应,导致自然杀伤(NK)细胞被激活并攻击癌细胞;由抗原呈递细胞展示的肿瘤和病毒相关抗原触发的特异性适应性免疫反应。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Wayne F. Pisano | Chairman of the Board | 2024 | 71 |
| Jared Kelly | CEO & Director | 2025 | - |
| Angela Frances Holtham | Independent Director | 2014 | 75 |
| Deborah M. Brown | Independent Director | 2017 | - |
| Jonathan M. N. Rigby | Independent Director | 2022 | 58 |
| Bernd Robert Seizinger | Independent Director | 2015 | 70 |
| Martine J. Piccart | Member of Scientific Advisory Board | 2017 | - |
| Padmanee Sharma | Member of Scientific Advisory Board | - | - |
| Richard Vile | Member of Scientific Advisory Board | 2020 | - |
| James T. Parsons | Independent Director | 2022 | 61 |
| Patricia S. Andrews | Independent Director | 2024 | 67 |
| Dirk Arnold | Member of Scientific Advisory Board | 2024 | - |
| Deva Mahalingam | Member of Scientific Advisory Board | 2025 | - |
| Sanjay Goel | Member of Scientific Advisory Board | 2025 | - |
| Eileen M. O’Reilly | Member of Gastrointestinal Tumor Scientific Advisory Board | 2026 | - |
| Neil H. Segal | Member of Gastrointestinal Tumor Scientific Advisory Board | 2026 | - |
| Van Morris | Member of Gastrointestinal Tumor Scientific Advisory Board | 2026 | - |